New drug listing treats rare life-threatening lung cancer
The Federal Minister for Health Sussan Ley recently announced that Crizotinib would be listed on the Pharmaceutical Benefit Scheme (PBS) from 1 July through a Managed Entry Scheme that would speed up access for patients with the highest need for treatment.
Ms Ley said Crizotinib (Xalkori®) was used to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer and would benefit approximately 154 patients with the rare life-threatening disease.
Ms Ley said introducing Crizotinib via a Managed Entry Scheme was a sensible way to provide early access to new breakthrough drugs patients with a high clinical need for treatment, whilst allowing the Pharmaceutical Benefits Advisory Committee to monitor its progress and collect data about the ongoing clinical benefits of this medicine to ensure it continued to deliver on what it promised.
XALKORI® (crizotinib) will be made available on the PBS for first and last-line patients with ALK positive non-small cell lung cancer (NSCLC), a rare form of lung cancer caused by a genetic mutation. It is a disease commonly found in non-smokers or light smokers (less than 10 packs a year).
For more information, click here.